While some patients experience adverse drug reactions (ADRs) when taking medicines, others do not, and in some cases, others do not receive therapeutic benefits from treatment regardless of dosage. One reason for this inter-individual variation in response is differences in genes that code for proteins important in drug response. This has given rise to the field of Pharmacogenomics (PGx), which seeks to identify biomarkers that predict drug response and apply them in the provision of PGx-guided precision medicine. Following years of repeated Pharmacogenomics (PGx) research, which sought to identify biomarkers…
Read MoreTag: efavirenz
DTG Won’t Be Forced On Citizens- Ministry
PEOPLE Living With HIV (PLHIV) and on Antiretroviral Therapy (ART) still have the option to continue taking other ART options apart from Dolutogravir (DTG) based regimens  since the process is not compulsory, a ministry of health and child care (MoHCC) official has said. By Michael Gwarisa in Gweru Zimbabwe commenced its transition process from Tenovir/Lamuvidene/Efavirens to Dolutegravir (DTG) in May 2019, and the transition procedure will be completed by February 2020. Briefing a women living with HIV, Sexual Reproductive Health and Rights (SRHR) workshop organised by PAPWC/ZIM,  ZWLHNF and UNAIDS,…
Read More#BREAKING: Zim To Switch To New ARV Drug With Less Side Effects
ZIMBABWE is ready to transition to Teno-Lamuvudine Dolutegrevir (TLD), an Anti-retro Viral (ARV) drug with less side effects, moving away from the Teno-Lamivudine-Efavirenz (TLE) a three in one drug that is taken once a day, a top health official has said By Michael Gwarisa The development comes barely a year after government through the Ministry of Health and Child Care (MoHCC) deferred rolling out of the Dolutegrevir drug following indications that it posed a great risk to women of child bearing age and adolescent girls which might lead to women…
Read More